Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical TrialRan Reshef, David Porter, Noelle V. Frey et al.|Transplantation and Cellular Therapy|2018Cited by 31
Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II StudyRan Reshef, David L. Porter, James K. Mangan et al.|Blood|2014Cited by 4
Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II StudyRan Reshef, David L. Porter, James K. Mangan et al.|Transplantation and Cellular Therapy|2017Cited by 1